FDA to review Vytorin cholesterol drug study
U.S. regulators said on Friday they would review a study showing a Merck and Schering-Plough cholesterol drug worked no better than a generic in preventing the build-up of arterial plaque.
Yoran helped form US-CERT, the government&#39;s cybersecurity information clearing house, but was reportedly frustrated with his post&#39;s limited authority and budgets.